Drilldown: Medicines

Nav

Choose a table:

Medicines (732)

Medicines > duration

: 24 h

or Hours per application

or ~12 weeks

Use the filters below to narrow your results.

None (1) · Bisoprolol (1) · Ciclopirox (1) · Clotrimazole (1) · Hydroquinone (1) · Memantine ER / Donepezil (1) · Mupirocin (1) · Nebivolol (1) · Nystatin (1)

Bactroban, Centany (1) · Botox (1) · Bystolic (1) · Lotrimin, Mycelex, Gyne-Lotrimin; OTC widely (1) · Lustra, EpiQuin Micro, Melquin, Tri-Luma (with tretinoin and fluocinolone) (1) · Mycostatin, Nystop, Nyamyc, Bio-Statin (1) · Namzaric (1) · Penlac (nail lacquer), Loprox (cream/lotion/shampoo) (1) · Zebeta (1)

Beta Blocker (2) · Cardioselective (β1) (1) · Cardioselective (β1) + vasodilator (1) · Combined cholinesterase inhibitor + NMDA antagonist (1) · neuromuscular blocker (presynaptic) (1) · Neurotoxin (1) · [[:Category:Antibacterials|Antibacterial]] (1) · [[:Category:Antifungals|Antifungal (imidazole)]] (1) · [[:Category:Antifungals|Antifungal]] (2) · [[:Category:Depigmenting_agents|Depigmenting agent]] (1) · [[:Category:Hydroxypyridones|Hydroxypyridone]] (1) · [[:Category:Polyene_antifungals|Polyene antifungal]] (1) · [[:Category:Skin_lightening_agents|Skin-lightening agent]] (1) · [[:Category:Topical_antibiotics|Topical antibiotic]] (1) · [[:Category:Topical_antifungals|Topical antifungal]] (2)

None (2) · Cleaves SNAP-25 protein in presynaptic motor and autonomic nerve terminals, blocking acetylcholine release; in chronic migraine, hypothesized to inhibit peripheral sensitization of trigeminovascular nociceptors (1) · Donepezil: reversible AChE inhibitor, increases synaptic acetylcholine. Memantine: uncompetitive low-affinity NMDA receptor antagonist, dampens pathological glutamate overactivation while preserving normal synaptic signaling. Targets two distinct mechanisms in Alzheimer's. (1) · Highly β1-selective adrenergic antagonist. Greater selectivity than metoprolol or atenolol. (1) · The d-enantiomer is a highly β1-selective antagonist; the l-enantiomer triggers endothelial nitric-oxide–mediated vasodilation. Unique among beta blockers for this NO mechanism. (1) · '"`UNIQ--vote-000009FD-QINU`"' Active against gram-positive cocci including MRSA; the unique target underlies the absence of cross-resistance with other antibiotic classes. High-level resistance (plasmid-mediated mupA) is rising and limits prolonged or repeated use'"`UNIQ--ref-000009FE-QINU`"'. (1) · '"`UNIQ--vote-00000D11-QINU`"' Same mechanistic family as amphotericin B but with prohibitive systemic toxicity at therapeutic doses, hence restriction to topical and luminal-gut indications. No clinically meaningful resistance after decades of use'"`UNIQ--ref-00000D12-QINU`"'. (1) · '"`UNIQ--vote-00001233-QINU`"' Onychomycosis cure rates with nail lacquer are modest (mycologic cure ~30-50%, complete cure ~5-12% at 48 weeks); oral terbinafine remains substantially more effective when systemic therapy is acceptable'"`UNIQ--ref-00001234-QINU`"'. (1)

2.5–5 mg daily (HTN); 1.25 mg daily (HFrEF, slow titration) (1) · 5 mg daily (1) · Apply thin layer to hyperpigmented areas BID; limit to 4-6 month courses to avoid ochronosis (1) · Chronic migraine (PREEMPT protocol): 155 units divided across 31 sites in 7 head/neck muscle groups every 12 weeks (1) · For patients already stable on memantine 28 mg/d + donepezil 10 mg/d, switch to one capsule daily of equivalent strength (1) · Oral: 4-6 mL (400,000-600,000 units) suspension QID swish-and-swallow; topical: BID-QID; vaginal tablet 1 daily for 2 weeks (1) · Topical cream/lotion BID; shampoo twice weekly; nail lacquer (Penlac) once daily for up to 48 weeks (1) · Topical: 1% cream BID × 2-4 weeks; vaginal: 1% or 2% cream nightly × 7 days, or 100/200/500 mg vaginal tablet single or 3-day regimens; troche: 10 mg PO five times daily × 2 weeks for thrush (1) · Topical: apply small amount to affected area TID × 5-10 days; nasal: apply half the contents of a single-use tube into each nostril BID × 5 days (1)

0.77% topical cream, lotion, suspension; 1% shampoo; 8% nail lacquer (Penlac) (1) · 1% topical cream, lotion, solution; 1%, 2% vaginal cream; 100, 200, 500 mg vaginal tablets; 10 mg oral troches; combination with betamethasone (Lotrisone, Rx) (1) · 100,000 units/mL oral suspension; 500,000 unit tablets; 100,000 units/g cream, ointment, powder; vaginal tablets (1) · 2% ointment; 2% cream; 2% nasal ointment (Bactroban Nasal) (1) · 2.5, 5, 10, 20 mg tabs (1) · 4% prescription cream/lotion; OTC 2% withdrawn in US (2020 CARES Act); compounded higher strengths available (1) · 5, 10 mg tabs (1) · 50, 100, or 200 unit vials of lyophilized powder for reconstitution (1) · 7/10, 14/10, 21/10, 28/10 mg ER capsules (memantine ER / donepezil) (1)

195 units/treatment for chronic migraine; max varies by problem (1) · 20 mg/d (1) · 28/10 mg/d (1) · 4% topical; limit duration of use (1) · 40 mg/d (1) · BID topical; once daily nail lacquer (1) · Indication-specific (1) · Limit topical to 10-day courses to reduce resistance pressure (1) · Topical: BID; troche: 5×/day (1)

Intramuscular (PREEMPT injections for migraine) (1) · intranasal (1) · Oral (2) · Oral (capsule whole or opened/sprinkled on applesauce) (1) · Oral (topical action; minimal systemic absorption) (1) · oral troche (1) · Topical (5) · vaginal (2)

1–2 h (2) · 1–2 weeks for muscle effects; preventive migraine benefit accrues over 12-week cycles (1) · Component effects accumulate over weeks (1) · Days (2) · Days for dermatophyte clearance; nail clearance over months (1) · Symptom relief within days (1) · Visible lightening at 4-12 weeks (1)

9–12 h (1) · Not meaningfully described (minimal systemic absorption from topical use)'"`UNIQ--ref-00000F45-QINU`"' (1) · Not meaningfully described (not systemically absorbed)'"`UNIQ--ref-00000D17-QINU`"' (1) · Not meaningfully described (topical local action)'"`UNIQ--ref-00001239-QINU`"' (1) · Not meaningfully described for topical use'"`UNIQ--ref-00000A02-QINU`"' (1) · Not meaningfully described — topical local action with minimal systemic absorption'"`UNIQ--ref-00001218-QINU`"' (1) · Tissue half-life not formally measured; clinical effect ~12 weeks (1) · ~10 h (CYP2D6 extensive metabolizers); up to 31 h (poor metabolizers) (1) · ~60–80 h (memantine); ~70 h (donepezil) (1)

Essentially zero systemic absorption from oral or topical routes — the topical-action-only profile is the basis of its safety'"`UNIQ--ref-00000D18-QINU`"' (1) · Local (intramuscular) (1) · Topical with limited but measurable systemic absorption'"`UNIQ--ref-00001219-QINU`"' (1) · Topical with minimal systemic absorption'"`UNIQ--ref-0000123A-QINU`"' (1) · Topical: minimal systemic; troche: ~3% systemic'"`UNIQ--ref-00000F46-QINU`"' (1) · Topical; minimal systemic absorption'"`UNIQ--ref-00000A03-QINU`"' (1) · ~100% both components (1) · ~12% (extensive metabolizers); ~96% (poor metabolizers) (1) · ~90% (low first-pass) (1)

Category C (2) · Category C; limited data (1) · Generally avoided in pregnancy.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe (minimal systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe in pregnancy (no systemic absorption).[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Generally considered safe; minimal systemic exposure.[[[Pharmacopedia:Citation needed|citation needed]]] (1) · Not relevant (geriatric problem) (1) · Topical and vaginal generally considered safe; widely used.[[[Pharmacopedia:Citation needed|citation needed]]] (1)

OTC (lower strengths) and [[USLegal:Prescription only|Rx-only]] (combination with betamethasone) in US (1) · Rx-only in US (3) · Rx; black-box warning for distant spread of toxin effect (1) · [[USLegal:Prescription only|Rx-only]] in US (3) · [[USLegal:Prescription only|Rx-only]] in US since 2020 (OTC 2% formulations withdrawn under CARES Act due to safety concerns) (1)